The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Low-Grade Glioma Market During The Forecast Period 2026–2030?

The market size for low-grade glioma has experienced significant growth over recent years. It is forecast to increase from $1.47 billion in 2025 to $1.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.9%. This historical expansion can be linked to progress in neuroimaging technologies, better survival outcomes for patients with low-grade glioma, higher rates of neurosurgical interventions, increasing public knowledge about brain tumor signs, and the expansion of oncology treatment facilities.

The low-grade glioma market is anticipated to experience robust expansion over the next few years. It is projected to reach $1.94 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period is fueled by an increasing emphasis on molecular tumor profiling, rising investments in targeted oncology drugs, a growing demand for less aggressive treatment options, expanding access to specialized neuro-oncology care, and ongoing clinical trials for novel therapies. Prominent trends for this period include a heightened focus on early diagnosis and monitoring, the growing adoption of targeted drug therapies, an increasing preference for multimodal treatment approaches, the expansion of personalized treatment planning, and the development of more effective long-term disease management strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Which Economic Or Industry Drivers Are Impacting The Low-Grade Glioma Market?

An increasing occurrence of brain tumors is projected to boost the expansion of the low-grade glioma market in the future. Brain tumors are characterized by unusual cell proliferation within the brain or its adjacent regions, which may be either non-cancerous or cancerous. This rising incidence of brain tumors stems from causes like heightened radiation exposure, environmental contaminants, genetic factors, and the aging process. Low-grade glioma offers assistance for brain tumors through the deployment of sophisticated diagnostic methods and specific treatments, including surgical removal, radiation therapy, and chemotherapy. These interventions are instrumental in decelerating tumor advancement, safeguarding neurological capabilities, and enhancing patient prognosis, underscoring the vital role of prompt diagnosis and tailored treatment for controlling other brain tumors that exhibit comparable growth characteristics. For example, in October 2025, data from Cancer Australia, an Australian government body, indicated that in 2023, Australia registered 1,597 deaths due to brain cancer, comprising 956 men and 641 women. This figure is projected to climb modestly to 1,639 deaths by 2025, with 979 men and 660 women. The anticipated likelihood of succumbing to brain cancer by age 85 in 2025 stands at 1 in 195 (0.51%), with males facing a greater risk at 1 in 165 (0.61%) and females a lesser risk at 1 in 240 (0.42%). Consequently, the increasing prevalence of brain tumors is propelling the expansion of the low-grade glioma market.

What Market Segments Are Evaluated Within The Low-Grade Glioma Market?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

What Key Trends Are Influencing The Development Of The Low-Grade Glioma Market?

Major companies within the low-grade glioma market are concentrating on integrating combination therapies with targeted approaches, such as genetic alteration drugs, to secure a competitive advantage and improve treatment for children suffering from low-grade glioma. These genetic alteration drugs are specialized targeted therapies designed to modify or inhibit specific genetic mutations or cellular abnormalities, thereby aiding in the treatment of diseases like cancer by obstructing pathways that drive uncontrolled cell proliferation. For instance, in May 2024, Day One Biopharmaceuticals, a biotechnology firm based in the US, introduced Tovorafenib (Ojemda) following its accelerated FDA approval. This targeted intervention is intended for children aged six months and older who have unresectable or recurrent low-grade glioma (LGG) accompanied by BRAF gene alterations. Its convenient once-weekly oral administration addresses a critical requirement for pediatric LGG patients who have had limited previous treatment alternatives.

Who Are The Top Market Participants Influencing The Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

Read the full low-grade glioma market report here:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

What Are The Top-Performing Regions Within The Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Low-Grade Glioma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2026, By The Business Research Company

Respiratory Devices And Equipment Therapeutic Global Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disease Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model